Long-term safety of granulocyte colony-stimulating factor in normal donors: Is it all clear?

Expert Opinion on Biological Therapy

Volumn 12, Issue 5, 2012, Pages 609-621

  Martino, Massimo ^a   Fedele, Roberta ^a   Massara, Elisabetta ^a   Recchia, Anna Grazia ^a,b   Irrera, Giuseppe ^a,b   Morabito, Fortunato ^a,b  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^b Haematology Unit   (Italy)

Author keywords

G CSF; healthy donors; long term safety; side effects

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

BLEEDING; BONE MARROW; BONE MARROW TRANSPLANTATION; CANCER RISK; COLON CARCINOMA; DONOR; FOLLOW UP; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOTHORAX; HORNER SYNDROME; HUMAN; INTRAVASCULAR CATHETER; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG CANCER; MONITORING; PNEUMOTHORAX; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; SUPRAVENTRICULAR TACHYCARDIA; THYROID CARCINOMA;

BLOOD DONORS; CLINICAL TRIALS AS TOPIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS;

EID: 84859610971     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.674937     Document Type: Review

References (130)

1. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011;46(4):485-501 Shows that the major change concerns the source of HPSCs itself.
2. Majolino I, Aversa F, Bacigalupo A, et al. Peripheral blood stem cells for allogeneic transplantation. Recommendations from the GITMO 1996. Gruppo Italiano trapianti di midollo osseo. Haematologica 1996;81(6):529-32
3. Pamphilon D, Mackinnon S, Nacheva E, et al. The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant 2006;38(10):699-700 (Pubitemid 44669686)
4. Pamphilon D, Nacheva E, Navarrete C, et al. The use of granulocyte-colony-stimulating factor in volunteer unrelated hemopoietic stem cell donors. Transfusion 2008;48(7):1495-501
5. Pamphilon D, Siddiq S, Brunskill S, et al. Stem cell donation - what advice can be given to the donor? Br J Haematol 2009;147(1):71-6
6. Confer DL, Abress LK, Navarro W, et al. Selection of adult unrelated hematopoietic stem cell donors: beyond HLA. Biol Blood Marrow Transplant 2010;16:S8-S11
7. Bensinger WI. Allogeneic transplantation: peripheral blood vs. bone marrow. Curr Opin Oncol 2011; [Epub ahead of print]
8. Stroncek DF, Holland PV, Bartch G, et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood 1993;81:1940-6 (Pubitemid 23101612)
9. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009;113:3604-11 Prospective follow-up data regarding the incidence of development of malignancies in HDs. High number of CVC placement.
10. Holig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009;114(18):3757-63 The largest study to date evaluating a prospective series of unrelated HDs supervised and followed up by a single apheresis center has been published.
11. Tigue CC, McKoy JM, Evens AM, et al. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the research on adverse drug events and reports project. Bone Marrow Transplant 2007;40:185-92 (Pubitemid 47108460)
12. Schmidt AH, Mengling T, Pingel J, et al. Follow-up of 12,559 unrelated donors of peripheral blood stem cells or bone marrow. Blood (ASH Annu Meet Abstr) 2010;116:abstract 365 Trial that compared with age- and gender-adjusted incidences of the German population.
13. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Peripheral blood stem cell (PBSC) donors experience higher levels ofpain and toxicities early on, while bone marrow (BM) donors experience slower recovery and more late pain: a prospective study of the National Marrow Donor Program (NMDP). Blood (ASH Annu Meet Abstr) 2010;116:abstract 1107
14. Switzer GE, Harrington BA, Haagenson MD, et al. Health related quality of life among adult matched unrelated stem cell donors: a Blood and Marrow Transplant Clinical Trials Network (BMT CTN) randomized trial of marrow versus PBSC donation. Blood (ASH Annu Meet Abstrs) 2010;116:abstract 366
15. Machaczka M, Kalaitzakis E, Eleborg L, et al. Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications. Bone Marrow Transplant 2010;45(1):53-61
16. Favre G, Beksac M, Bacigalupo A, et al. Differences between graft product and donor side effects following bone marrow or stem cell donation. Bone Marrow Transplant 2003;32(9):873-80 (Pubitemid 37369264)
17. Buckner CD, Clift RA, Sanders JE, et al. Marrow harvesting from normal donors. Blood 1984;64(3):630-4 (Pubitemid 14073480)
18. Hosoya N, Miyagawa K, Mimura T, et al. Malignant hyperthermia induced by general anesthesia for bone marrow harvesting. Bone Marrow Transplant 1997;19:509-11 (Pubitemid 27102021)
19. Kessinger A, Smith DM, Strandjord SE, et al. Allogeneic transplantation of blood-derived, T cell-depleted hematopoietic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone Marrow Transplant 1989;4:643-6 The first reported case of allogeneic PB HPSC transplantation. (Pubitemid 20020748)
20. Socinski MA, Cannistra SA, Elias A, et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;28:1194-8
21. Duhrsen U, Villeval J-L, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81 (Pubitemid 19030905)
22. Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993;82:1981-4 (Pubitemid 23293976)
23. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 1993;81:1883-8 (Pubitemid 23101604)
24. Korbling M, Prezpiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukaemia and lymphoma: potential advantage of blood over marrow graft. Blood 1995;85:1659-65
25. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cellsmobilized by recombinant human granulocyte colony stimulating factor. Blood 1995;85(6):1655-8
26. Demirer T, Bensinger WI, Buckner CD. Peripheral blood stem cell mobilization for high dose chemotherapy. J Hematother 1999;8:103-13 (Pubitemid 29232633)
27. Anderlini P, Donato M, Lauppe MJ, et al. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 2000;109(4):770-2 (Pubitemid 30609754)
28. Martinez C, Urbano-Ispizua A, Marin P, et al. Efficacy and toxicity of a high-dose GCSF schedule for peripheral blood progenitor cell mobilization in healthy donors. Bone Marrow Transplant 1999;24:1273-8 (Pubitemid 30052781)
29. Kroger N, Zander AR. Dose and schedule effect of G-GSF for stem cell mobilization in healthy donors for allogeneic transplantation. Leuk Lymphoma 2002;43:1391-4 (Pubitemid 34705022)
30. Engelhardt M, Bertz H, Afting M, et al. High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection. J Clin Oncol 1999;17:2160-72 (Pubitemid 29318849)
31. Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor. Lancet 1999;353(9152):555 (Pubitemid 29078428)
32. Barosi G, Bosi A, Abbracchio MP, et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 2011;96(7):937-42
33. Shaw BE, Confer DL, Hwang WY, et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011;96(7):942-7
34. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008;112(4):990-8
35. Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies Clinical. Trials.gov Identifier. NCT00241358. Available from: http://clinicaltrials.gov/ct2/show/study/ NCT01403896
36. Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) - what is the difference? Med Oncol 1998;15:229-33 (Pubitemid 29049186)
37. Ketley NJ, Newland AC. Haemopoietic growth factors. Postgrad Med J 1997;73:215-21 (Pubitemid 27156760)
38. Pedrazzoli P, Gibelli N, Pavesi L, et al. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells. Anticancer Res 1996;16:1781-5 (Pubitemid 26270684)
39. Martin-Christin F. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs 2001;12:185-91 (Pubitemid 32269913)
40. Tanaka H, Tanaka Y, Shinagawa K, et al. Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine 1997;9:360-9 (Pubitemid 27248246)
41. Nohynek GJ, Plard JP, Wells MY, et al. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats. Cancer Chemother Pharmacol 1997;39:259-66 (Pubitemid 26414265)
42. Martino M, Console G, Irrera G, et al. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher 2005;20(3):129-36 (Pubitemid 43081860)
43. Schiodt I, Knudsen LM, Jensen L, et al. Flow cytometry comparison of CD34+ subsets in bone marrow and peripheral blood after priming with glycosylated or non-glycosylated rhG-CSF. Bone Marrow Transplant 1998;21:1167-70
44. Hoglund M, Smedmyr B, Bengtsson M, et al. Mobilization of CD34+ cells by glycosylated and non-glycosylated G-CSF in healthy volunteers. A comparative study. Eur J Haematol 1997;59:177-83 (Pubitemid 27392094)
45. Watts MJ, Addison I, Long SG, et al. Crossover study of the haematological effects and pharmacokinetics of glycosylated and non-glycosylated G-CSF in healthy volunteers. Br J Haematol 1997;98:474-9.357-360
46. Fischer JC, Frick M, Wassmuth R, et al. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005;130(5):740-6 (Pubitemid 43906646)
47. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339(8794):640-4
48. To LB, Roberts MM, Haylock DN, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9(4):277-84
49. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006;108(13):4288-90 (Pubitemid 44913306)
50. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344(3):175-81 (Pubitemid 32064138)
51. Zhang H, Chen J, Que W. Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: Meta-analysis of randomized controlled trials. Leuk Res 2011; Epub ahead of print
52. Chang YJ, Weng CL, Sun LX, et al. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Ann Hematol 2011; Epub ahead of print
53. Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparingperipheral stem cells to bone marrow using unrelated donors. Blood 2001;98:1739-45
54. Garderet L, Labopin M, Gorin NC, et al. Patients with acute lymphoblastic leukemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood progenitor cell graft compared to bone marrow. Bone Marrow Transplant 2003;31:23-9
55. Anasetti C, Logan BR, Lee SJ, et al. Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and no survival advantage with filgrastim-mobilized Peripheral Blood Stem Cells (PBSC) compared to Bone Marrow (BM) transplants from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. ASH; 2011 The first prospective randomized trial to compare PB with BM HPSC transplants from unrelated donors.
56. Anderlini P, Rizzo JD, Nugent ML, et al. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001;27(7):689-92 Indicates a higher number of CVC placement. (Pubitemid 32409442)
57. Rowley SD, Donaldson G, Lilleby K, et al. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001;97(9):2541-8
58. Karlsson L, Quinlan D, Guo D, et al. Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue. Bone Marrow Transplantation 2004;33:709-13 (Pubitemid 38499924)
59. Siddiq S, Pamphilon D, Brunskill S, et al. Bone marrow harvest versus peripheral stem cell collection for haemopoietic stem cell donation in healthy donors. Cochrane Database Syst Rev 2009;21(1):CD006406
60. Anderlini P, Przepiorka D, Seong D, et al. Clinical toxicity and laboratory effects of G-CSF mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion 1996;36:590-5 (Pubitemid 26256425)
61. Stroncek D, Clay M, Petzold M, et al. Treatment of normal individuals with GCSF: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion 1996;36:601-10 (Pubitemid 26256427)
62. Martino M, Morabito F, Callea I, et al. Harvesting peripheral blood progenitor cells from healthy donors with a short course of recombinant human granulocyte-colony-stimulating factor. Transfus Med 2005;15:323-8 (Pubitemid 41633122)
63. Martino M, Console G, Dattola A, et al. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience. Bone Marrow Transplant 2009;44(3):163-8 Trial with one of the longest follow-ups of such donors to date.
64. Murata M, Harada M, Kato S, et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors. Bone Marrow Transplant 1999;24:1065-71
65. Halter J, Kodera Y, Ispizua AU, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 2009;94(1):94-101 The largest retrospective study.
66. Bensinger W, Buckner W, Rowley S, et al. Treatment of normal donors with recombinant growth factors for transplantation of allogeneic blood stem cells. Bone Marrow Transplant 1996;17:S19-21 (Pubitemid 26125730)
67. Shimoda K, Okamura S, Haarada N, et al. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest 1993;91:1310
68. Horowitz MM, Confer DL. Evaluation of hematopoietic stem cell donors. Hematology Am Soc Hematol Educ Program 2005;469-75
69. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony stimulating factor. Blood 1999;93:2506-14 (Pubitemid 29181182)
70. Martino M, Massara E, Irrera G, et al. Pulmonary micro-embolism in a healthy donor following G-CSF administration for mobilization of hemopoietic progenitor cells. Bone Marrow Transplant 2011; [Epub ahead of print]
71. Dejesus CE, Egen J, Metzger M, et al. Transient neutropenia after granulocyte-colony stimulating factor administration is associated with neutrophil accumulation in pulmonary vasculature. Exp Hematol 2011;39:142-50
72. Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of G-CSF: occurrence in an allogeneic donor of peripheral blood stem cells. Biol Blood Marrow Transplant 1997;3:45
73. Stroncek D, Shawker T, Folman D, et al. G-CSF induced spleen size changes in PBPC donors. Transfusion 2003;43:609-13
74. Tassi C, Razzari PL, Bonifazi F, et al. Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 2005;36:289-94 (Pubitemid 41195160)
75. Stroncek DF, Clay ME, Herr G, et al. Blood counts in healthy donors 1 year after the collection of granulocyte-colony stimulating factor mobilized progenitor cells and the results of a second mobilization and collection. Transfusion 1997;37:304-8 (Pubitemid 27142859)
76. de la Rubia J, de Arriba F, Arbona C, et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica 2008;93:735-40 (Pubitemid 351669314)
77. Hasenclever D, Sextro M. Safety of AlloPBPCT donors: biometrical considerations on monitoring long term risks. Bone Marrow Transplant 1996;17:28-30
78. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol 2007;137(1):77-8 (Pubitemid 46426404)
79. Izraeli S. Could rhG-CSF induction of tetraploidy contribute to leukemogenesis in healthy donors?. Br J Haematol 2007;138(4):558 (Pubitemid 47063036)
80. Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood 2008;111(4):1767-72 (Pubitemid 351451480)
81. Avalos BR, Lazaryan A, Copelan EA. Can G-CSF Cause Leukemia in Hematopoietic Stem Cell Donors? Biol Blood Marrow Transplant 2011;17(12):1739-46
82. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood 1991;78:2791-808
83. Avalos BR. Molecular analysis of the granulocyte colony stimulating factor receptor. Blood 1996;88:761-77 (Pubitemid 26333294)
84. Christopher MJ, Rao M, Liu F, et al. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 2011;208:251-60
85. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006;99:690-705 (Pubitemid 44521989)
86. White SM, Ball ED, Ehman WC, et al. Increased expression of the differentiation-defective granulocyte colony-stimulating factor receptor mRNA isoform in acute myelogenous leukemia. Leukemia 1998;12:899-906 (Pubitemid 28287213)
87. Metcalf D. The colony stimulating factors: discovery, development, and clinical applications. Cancer 1990;65:2185-95 (Pubitemid 20164821)
88. Shapira MY, Kaspler P, Samuel S, et al. Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol 2003;73:33-6 (Pubitemid 36504575)
89. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colonystimulating factor (2). N Engl J Med 1992;327:99-106.82
90. Brodsky RA, Bedi A, Jones RJ. Are growth factors leukemogenic? Leukemia 1996;10:175-7 (Pubitemid 26052998)
91. Lindemann M, Rebmann V, Ottinger H, et al. rhG-CSF effect on mixed lymphocyte cultures and circulating soluble HLA antigen levels in volunteer stem cell donors. Exp Hematol 2004;32(11):1103-9 (Pubitemid 39469935)
92. Rutella S, Rumi C, Pierelli L. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp Hematol 2000;28(6):612-25 (Pubitemid 30398519)
93. Cesaro S, Marson P, Messina C. Granulocyte-colony-stimulating factor-stimulated healthy donors and leukaemia risk. [letter]. Vox Sang 2003;85:125 (Pubitemid 37092785)
94. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003;101:3862-7 (Pubitemid 36857858)
95. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia: AML Cooperative Study Group. N Engl J Med 1995;332:1678-83
96. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996;14:1371-2
97. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998;91:3607-15 (Pubitemid 28225726)
98. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia: the International Acute Myeloid Leukemia Study Group. Blood 1997;90:4710-18 (Pubitemid 28007183)
99. Legare RD, Gribben JG, Maragh M, et al. Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am J Hematol 1997;56:45-51 (Pubitemid 27398059)
100. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102:43-52 (Pubitemid 36759634)
101. Harrison CN, Gregory W, Hudson GV, et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 1999;81:476-83 (Pubitemid 29458802)
102. Milligan DW, Ruiz De Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 1999;106:1020-6
103. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 2003;101:2015-23 (Pubitemid 36237609)
104. van de Geijn GJ, Aarts LH, Erkeland SJ, et al. Granulocyte colony-stimulating factor and its receptor in normal hematopoietic cell development and myeloid disease. Rev Physiol Biochem Pharmacol 2003;149:53-71
105. Touw IP, Bontenbal M. Granulocyte colony-stimulating factor: key factor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 2007;99:183-6
106. Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood 2007;109:2794-6 (Pubitemid 46482073)
107. Kojima S, Ohara A, Tsuchida M. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002;100:786-90 (Pubitemid 34832602)
108. Freedman MH, Alter BP. Malignant myeloid transformation in congenital forms of neutropenia. Isr Med Assoc J 2002;4:1011-14
109. Nagler A, Korenstein-Ilan A, Amiel A, et al. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol 2004;32:122-30 (Pubitemid 38064408)
110. Hernandez JM, Castilla C, Gutierrez NC, et al. Mobilization with G-CSF in healthy donors promotes a high but temporal deregulation of genes [letter]. Bone Marrow Transplant 2006;38:699-700
111. Kaplinsky C, Trakhtenbrot L, Hardan I, et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG- CSF. Bone Marrow Transplant 2003;32:31-4
112. Hirsch B, Oseth L, Cain M, et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood 2011;118(9):2602-8
113. Donadieu J, Leblanc T, Meunier BB, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French severe chronic neutropenia study group. Haematologica 2005;90(1):45-53
114. De Jong D, Voetdijk BMH, Beverstock GC, et al. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N Engl J Med 1988;318:1373
115. Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t (14;18) in blood B cells of normal individuals. Blood 1995;85(9):2528-36 Shows that t(14; 18) breakpoints are present in blood cells of healthy individuals, so they proved that such translocations could occur beyond any context of malignancy.
116. Pamphilon D, Mackinnon S, Nacheva E, et al. The use of granulocyte colonystimulating factor in volunteer blood and marrow registry donors [letter]. Bone Marrow Transplant 2006;38:699-700 (Pubitemid 44669686)
117. Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006;135(5):642-50 (Pubitemid 44674074)
118. Makita K, Ohta K, Mugitani A, et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant 2004;33:661-5 (Pubitemid 38455931)
119. Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 2000;25(1):85-9 (Pubitemid 30093161)
120. Anderlini P, Chan FA, Champlin RE, et al. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 2002;30(10):661-3 (Pubitemid 35446647)
121. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration [letter]. Br J Haematol 2007;137:77-8 Shows that the incidence of cancer in this group was consistent with the age-adjusted US incidence of cancer in the adult population, with no reports of hematological disease. (Pubitemid 46426404)
122. Jeger A, Favre G, Lutz JM, et al. Tumor incidence in related hematopoietic stem cell donors. Bone Marrow Transplant 2011;46(9):1240-4
123. Anderlini P. Effects and safety of granulocyte colony-stimulating factor in healthy volunteers. Curr Opin Hematol 2009;16(1):35-40
124. Goldin LR, Caporaso NE. Family studies in chronic lymphocytic leukaemia and other lymphoproliferative tumours. Br J Haematol 2007;139:774-9 Shows an increased familial risk for hematological malignancies as well as an association of the HLA system. (Pubitemid 350119794)
125. Pang D, Alston RD, Eden TOB, et al. Cancer risks among relatives of children with Hodgkin and non-Hodgkin lymphoma. Int J Cancer 2008;123:1407-10 Shows an increased familial risk for hematological malignancies as well as an association of the HLA system.
126. Craddock C. Enshrining donor rights and optimizing patient outcome in unrelated donor transplantation. Bone Marrow Transplant 2011;46(1):17
127. Sacchi N, Costeas P, Hartwell L, et al. Haematopoietic stem cell donor registries: world Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 2008;42(1):9-14 (Pubitemid 352003419)
128. van Rood JJ, Oudshoorn M. When selecting an HLA mismatched stem cell donor consider donor immune status. Curr Opin Immunol 2009;21(5):538-43
129. Woolf SH. Shared decision-making: the case for letting patients decide which choice is best. J Fam Pract 1997;45:205-8
130. Laine C, Davidoff F. Patient-centered medicine: a professional evolution. JAMA 1996;275:152-6 (Pubitemid 26021686)